A 3-year follow-up study of canakinumab in frequently flaring gouty arthritis patients, contraindicated, intolerant, or unresponsive to nonsteroidal anti-inflammatory drugs and / or colchicine [abstract] - Schlesinger, N; Bardin, T; Bloch, M (Arthritis Rheumatol, 2015)
letzter Zugriff: 26.05.2016